Key result
DCB-based PCI showed a trend toward a lower rate of target vessel failure compared to DES-only angioplasty for coronary CTOs (0.45% vs 0.76% person-months; IRR 0.56; 95% CI 0.28-1.10; p=0.09).
Its licence doesn't allow us to show a copy here.
Why the study?
The clinical performance of drug-coated balloon-based PCI compared to drug-eluting stent-only angioplasty for coronary chronic total occlusions remains uncertain.
Does DCB-based PCI reduce target vessel failure in patients with coronary chronic total occlusions compared to DES-only angioplasty?
Meta-Analysis (n=2,087)
Does DCB-based PCI reduce target vessel failure in patients with coronary chronic total occlusions compared to DES-only angioplasty?
Relative Risk: 0.56 (95% CI 0.28–1.1)
Absolute Event Rate: 0.45% vs 0.76%
p-value: p=0.09
In a meta-analysis of observational studies, DCB-based PCI was associated with similar outcomes compared to second-generation DES for the treatment of coronary CTOs, with a non-significant trend toward lower target vessel failure.
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is associated with worse outcomes compared to non-CTO lesions. Whether the implantation of drug-eluting stents (DES) is the cornerstone treatment after successful recanalization of CTO, recent evidence tested the clinical performance of DCB-based PCI, alone or in concert with DES (hybrid DCB/DES approach), in this context. We aimed to conduct a comprehensive, up-to-date systematic review and summary-level meta-analysis of clinical studies comparing outcomes of DCB-based versus DEB-only angioplasty for coronary CTOs. A systematic search was performed to identify all investigations comparing DCB-based versus DES-only angioplasty for coronary CTOs. The primary endpoint was the occurrence of target vessel failure (TVF), a composite outcome of cardiac death, nonfatal myocardial infarction and target vessel revascularization . A total of 5 observational studies (2087 patients) were included in the analysis. The DCB-based PCI group experienced a trend towards a lower rate of TVF (0.45 % (112/25045) vs. 0.76 % (238/31336) person-months, IRR = 0.56 [95 % CI 0.28 to 1.10], I 2 = 81 %, p = 0.09) and cardiac death (0.05 % vs. 0.10 % person-months, IRR = 0.55 [95 % CI 0.27 to 1.10], I 2 = 0 %, p = 0.09), although a high extent of heterogeneity was observed. Other endpoints were not different between the two groups. In the present meta-analysis, DCB-based PCI was associated with similar outcomes compared to second-generation DES PCI for the treatment of coronary CTOs. Future randomized controlled trials will provide more robust evidence on the effectiveness of DCB in treating coronary CTOs.
No takes yet. Share an insight, caveat, or question.
Gurgoglione et al. (2025) conducted a meta-analysis in Coronary chronic total occlusion (CTO) (n=2,087). DCB-based PCI vs. DES-only angioplasty was evaluated on Target vessel failure (TVF), a composite outcome of cardiac death, nonfatal myocardial infarction and target vessel revascularization (IRR 0.56, 95% CI 0.28 to 1.10, p=0.09). DCB-based PCI showed a trend toward a lower rate of target vessel failure compared to DES-only angioplasty for coronary CTOs (0.45% vs 0.76% person-months; IRR 0.56; 95% CI 0.28-1.10; p=0.09).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: